Skip to main content

Table 4 Cumulated percentage of patients reporting ≥ 3 upper respiratory tract infections and ≥ 3 acute otitis media episodes during the study period

From: A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections

Infection

Month

1 (%)

2 (%)

3 (%)

4 (%)

5 (%)

6 (%)

URTI

 Group A treatment 3 months

0

5

12*

14*

18*

21*

 Group B placebo

0

7

22

31

40

52

 Group C treatment 6 months

0

6

11*

15*

16*

17*

AOM

 Group A treatment 3 months

0

2

6*

13*

19*

21*

 Group B placebo

0

4

15

24

36

44

 Group C treatment 6 months

0

3

7*

12*

16*

19*

  1. AOM: acute otitis media; URTI: upper respiratory tract infection
  2. * p < 0.05 vs placebo; no other significant differences between the groups
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us